Zacks Investment Research upgraded shares of Keryx Biopharmaceuticals (NASDAQ:KERX) from a sell rating to a hold rating in a research report released on Friday morning.

According to Zacks, “Keryx’s loss in third-quarter 2017 was wider than expected while sales missed estimates. The FDA approval for the label expansion of Auryxia to treat adults with iron deficiency anemia (IDA) and chronic kidney disease, not on dialysis, might boost sales of the company, given that the IDA market holds great potential. With the latest approval, this drug can treat two complications of chronic kidney disease. The company also believes that the formulary additions at two major Part D providers will continue to support and drive the future growth of Aurexia. The company is also conducting few studies for further label expansion of the drug which should bode well for it. “

Other analysts have also recently issued research reports about the stock. BidaskClub raised shares of Keryx Biopharmaceuticals from a sell rating to a hold rating in a research note on Wednesday, August 16th. ValuEngine cut shares of Keryx Biopharmaceuticals from a hold rating to a sell rating in a research note on Thursday, September 21st. Finally, Stifel Nicolaus reduced their price objective on shares of Keryx Biopharmaceuticals from $7.00 to $5.00 and set a hold rating on the stock in a research note on Wednesday, November 8th. One analyst has rated the stock with a sell rating, six have issued a hold rating and one has given a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and an average target price of $7.35.

Shares of Keryx Biopharmaceuticals (NASDAQ KERX) remained flat at $$4.79 during trading hours on Friday. The company’s stock had a trading volume of 1,423,800 shares, compared to its average volume of 1,530,004. The company has a debt-to-equity ratio of 13.95, a quick ratio of 3.76 and a current ratio of 4.46. Keryx Biopharmaceuticals has a one year low of $4.47 and a one year high of $8.38.

Keryx Biopharmaceuticals (NASDAQ:KERX) last issued its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.03). Keryx Biopharmaceuticals had a negative return on equity of 10,954.62% and a negative net margin of 323.92%. The business had revenue of $15.00 million during the quarter, compared to the consensus estimate of $18.88 million. During the same period in the prior year, the firm earned ($0.39) EPS. The business’s revenue for the quarter was up 138.1% compared to the same quarter last year. research analysts predict that Keryx Biopharmaceuticals will post -1.36 EPS for the current fiscal year.

A number of large investors have recently bought and sold shares of KERX. Fox Run Management L.L.C. purchased a new stake in shares of Keryx Biopharmaceuticals during the 3rd quarter worth approximately $101,000. Engineers Gate Manager LP bought a new position in Keryx Biopharmaceuticals in the 3rd quarter worth approximately $102,000. Principal Financial Group Inc. boosted its holdings in Keryx Biopharmaceuticals by 4.2% in the 2nd quarter. Principal Financial Group Inc. now owns 14,759 shares of the biopharmaceutical company’s stock valued at $107,000 after purchasing an additional 590 shares during the period. Raymond James Financial Services Advisors Inc. boosted its holdings in Keryx Biopharmaceuticals by 51.8% in the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 16,495 shares of the biopharmaceutical company’s stock valued at $119,000 after purchasing an additional 5,628 shares during the period. Finally, Legal & General Group Plc boosted its holdings in Keryx Biopharmaceuticals by 1.2% in the 1st quarter. Legal & General Group Plc now owns 25,985 shares of the biopharmaceutical company’s stock valued at $161,000 after purchasing an additional 300 shares during the period. Hedge funds and other institutional investors own 64.83% of the company’s stock.

TRADEMARK VIOLATION WARNING: This story was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another domain, it was illegally stolen and republished in violation of US and international copyright and trademark legislation. The original version of this story can be read at https://www.thecerbatgem.com/2017/12/04/keryx-biopharmaceuticals-kerx-upgraded-at-zacks-investment-research.html.

Keryx Biopharmaceuticals Company Profile

Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.

Get a free copy of the Zacks research report on Keryx Biopharmaceuticals (KERX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Keryx Biopharmaceuticals (NASDAQ:KERX)

Receive News & Stock Ratings for Keryx Biopharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals Inc. and related stocks with our FREE daily email newsletter.